Buspirone for Agitation in Dementia
Buspirone is not recommended as a first-line or evidence-based treatment for agitation in dementia, as it lacks support from major clinical guidelines and has minimal high-quality evidence demonstrating efficacy for this indication.
Guideline-Based Approach
The APA 2016 guidelines explicitly focus on antipsychotics as the primary pharmacological intervention for severe agitation in dementia, with no mention of buspirone 1. The structured approach mandates:
Step 1: Non-Pharmacological Interventions First
- Assess for pain, environmental triggers, and modifiable contributors before any medication 1
- Review response to non-pharmacological interventions prior to pharmacological treatment 1
Step 2: Reserve Pharmacotherapy for Severe Cases
- Use antipsychotic medication only when symptoms are severe, dangerous, or cause significant distress 1
- This is a conditional recommendation (1B evidence level)
Step 3: If Medication is Necessary
The guidelines recommend antipsychotics (risperidone, aripiprazole, olanzapine) as the evidence-based pharmacological option, not buspirone 1
Why Buspirone Falls Short
Limited and Low-Quality Evidence
The available research on buspirone consists primarily of:
- Small open-label studies from the 1990s with 10-26 patients 2, 3, 4
- One retrospective chart review of 179 patients showing 68.6% response rate, but this lacks the rigor of controlled trials 5
- A single small double-blind trial (n=26) comparing buspirone to haloperidol, which showed some benefit for tension/anxiety but lacked a placebo control 2
FDA Labeling Concerns
The FDA label for buspirone explicitly states:
- "Buspirone has no established antipsychotic activity and should not be employed in lieu of appropriate antipsychotic treatment" 6
- It is approved only for generalized anxiety disorder, not agitation or dementia-related behaviors 6
Safety Considerations from Drug Label
While buspirone may have a favorable side effect profile compared to antipsychotics, important warnings include:
- Risk of serotonin syndrome, particularly with concomitant serotonergic medications 6
- Potential for restlessness and akathisia shortly after initiation 6
- Contraindicated with MAOIs due to risk of elevated blood pressure 6
Recent Evidence Context
The 2025 JAGS systematic review on severe agitation in geriatric emergency settings found benzodiazepines (particularly midazolam) pose excessive risk, with quetiapine showing the lowest adverse event profile among studied agents 7. Notably, buspirone was not included in this analysis of medications for severe agitation, further highlighting its lack of evidence base for this indication.
The 2026 Taiwan consensus and 2025 Korean guidelines both recommend brexpiprazole, risperidone, aripiprazole, and select antidepressants (citalopram) for agitation in dementia, with no mention of buspirone 8, 9.
Clinical Bottom Line
If you are considering buspirone:
- Recognize it is an off-label use without guideline support
- The evidence base consists of decades-old, small, uncontrolled studies
- It may have a role in mild anxiety symptoms in dementia patients (not severe agitation)
- Doses studied ranged from 15-60 mg/day, with most benefit at 25-35 mg/day 5, 4
For agitation requiring pharmacological intervention:
- Follow APA guidelines: use antipsychotics (risperidone 0.5-2 mg/day, aripiprazole 5-15 mg/day) for severe, dangerous agitation 1
- Consider citalopram 10-30 mg/day if depression/anxiety underlies agitation 9
- Reassess after 4 weeks; discontinue if no response 1
Common Pitfall
Do not use buspirone as a "safer alternative" to antipsychotics for severe agitation—this lacks evidence and delays appropriate treatment. The FDA explicitly warns against substituting buspirone for antipsychotic treatment when indicated 6.